Our news - IRCCS

Studies on data Published on 30/06/2025

Presentation of 2 posters at the LUGANO 2025 congress

Pr. Hervé GHESQUIÈRES: Synthetic control arm from clinical trial and real-world cohorts from LYSA group for untreated older classical Hodgkin lymphoma for innovative clinical trial designs Dr. Estelle BOURBON: Impact of Response to Holding/Bridging Therapy in Second-line DLBCL Patients Treated with Axicabtagene ciloleucel: a LYSA Study from the French DESCAR-T Registry

Clinical trials Events Published on 30/06/2025

Pr Hervé GHESQUIÈRES in the spotlight: oral participation at LUGANO 2025

Final analysis of the Lysa Phase II TIRHOL BGB-A317-210 study: TISLELIZUMAB, an anti-PD-1 antibody in patients with relapsed or refractory classical Hodgkin lymphoma.

Clinical trials Events Published on 30/06/2025

Pr Emmanuel BACHY : communication at LUGANO congress

Extended follow-up results for GOLCADOMIDE + rituximab in patients with relapsed/refractory (R/R) DLBCL in the Phase 1/2 CC-99282-NHL-001 study (NCT03930953).

Clinical trials Events Published on 30/06/2025

Professor Emmanuel BACHY oral communication during the LUGANO congress

Primary results for patients with relapsed/refractory (R/R) FL treated with valemetostat in the open-label, single-arm, phase 2 VALYM study

Events Published on 05/05/2025

It all started with clinical trials…

Leaders in CAR-T cell treatment, HCL treats its 500th adult patient with this revolutionary therapy

Clinical trials Published on 01/05/2025

TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomas

Pierre Stephan, Roberta Di Blasi, Louise Roulin, Jean Galtier, Julien Calvani, Veronique Meignin, Marie Donzel, Alexandra Traverse-Glehen, Elsa Poullot, Marie-Cécile Parrens, Vivien Dupont, Alexandra Marquet, Steven Le Gouill , Roch Houot, Francois-Xavier Gros, François Lemonnier, Emmanuel Bachy, Catherine Thieblemont, Pierre Sesques

Studies on data Published on 24/04/2025

Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?

Nicolas Gazeau, David Beauvais, Rémi Tilmont, Micha Srour, Emmanuelle Ferrant, Violaine Safar, Ludovic Fouillet, Pascale Flandrin-Gresta, Nicolas Gower, Paul Chauvet, Nicolas Duployez, Benjamin Podvin, Julie Demaret, Sarah Huet, Pierre Sujobert, Hervé Ghesquières, Gandhi Damaj, Emmanuel Bachy, Franck Morschhauser, Ibrahim Yakoub-Agha, Maël Heiblig, Pierre Sesques

Clinical trials Published on 03/04/2025

Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study

Guillaume Cartron, Roch Houot, Yassine Al Tabaa, Fabien Le Bras, Loïc Ysebaert, Sylvain Choquet, Fabrice Jardin, Jacques-Olivier Bay, François-Xavier Gros, Franck Morschhauser, Olivier Casasnovas, Thomas Gastinne, Catherine Thieblemont, Magalie Joris, Laure Ricard, Caroline Regny, Laurianne Drieu La Rochelle, Pierre Feugier, Ambroise Marcais, Samuel Griolet, Karin Tarte, Camille Laurent, Pierre Sesques